Levodopa therapy for Parkinson disease: A look backward and forward
- PMID: 27044648
- DOI: 10.1212/WNL.0000000000002509
Levodopa therapy for Parkinson disease: A look backward and forward
Abstract
Although levodopa is widely recognized as the most effective therapy for Parkinson disease (PD), its introduction 5 decades ago was preceded by several years of uncertainty and equivocal clinical results. The translation of basic neuroscience research by Arvid Carlsson and Oleh Hornykiewicz provided a logical pathway for treating PD with levodopa. Yet the pioneering clinicians who transformed PD therapeutics with this drug--among them Walther Birkmayer, Isamu Sano, Patrick McGeer, George Cotzias, Melvin Yahr, and others--faced many challenges in determining whether the concept and the method for replenishing deficient striatal dopamine was correct. This article reviews highlights in the early development of levodopa therapy. In addition, it provides an overview of emerging drug delivery strategies that show promise for improving levodopa's pharmacologic limitations.
© 2016 American Academy of Neurology.
Similar articles
-
Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.Mov Disord. 2015 Jan;30(1):19-36. doi: 10.1002/mds.26120. Epub 2014 Dec 8. Mov Disord. 2015. PMID: 25488030 Review.
-
The medical treatment of Parkinson disease from James Parkinson to George Cotzias.Mov Disord. 2015 Jan;30(1):4-18. doi: 10.1002/mds.26102. Epub 2014 Dec 9. Mov Disord. 2015. PMID: 25491387 Review.
-
New levodopa therapeutic strategies.Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S37-40. doi: 10.1016/j.parkreldis.2015.09.021. Epub 2015 Sep 8. Parkinsonism Relat Disord. 2016. PMID: 26459662 Review.
-
Classics in chemical neuroscience: levodopa.ACS Chem Neurosci. 2014 Dec 17;5(12):1192-7. doi: 10.1021/cn5001759. Epub 2014 Oct 10. ACS Chem Neurosci. 2014. PMID: 25270271 Review.
-
Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease.Neurology. 2013 May 7;80(19):1754-61. doi: 10.1212/WNL.0b013e3182918c2d. Epub 2013 Apr 10. Neurology. 2013. PMID: 23576623 Clinical Trial.
Cited by
-
Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation.Clin Park Relat Disord. 2023 Apr 24;8:100197. doi: 10.1016/j.prdoa.2023.100197. eCollection 2023. Clin Park Relat Disord. 2023. PMID: 37181100 Free PMC article.
-
Neurotheranostics as personalized medicines.Adv Drug Deliv Rev. 2019 Aug;148:252-289. doi: 10.1016/j.addr.2018.10.011. Epub 2018 Oct 26. Adv Drug Deliv Rev. 2019. PMID: 30421721 Free PMC article. Review.
-
Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson's disease: post-hoc analysis of a Japanese phase III study.J Neural Transm (Vienna). 2022 Oct;129(10):1277-1287. doi: 10.1007/s00702-022-02532-2. Epub 2022 Aug 24. J Neural Transm (Vienna). 2022. PMID: 36001147 Free PMC article. Clinical Trial.
-
Alpha-Synuclein and Mitochondrial Dysfunction in Parkinson's Disease: The Emerging Role of VDAC.Biomolecules. 2021 May 11;11(5):718. doi: 10.3390/biom11050718. Biomolecules. 2021. PMID: 34064816 Free PMC article. Review.
-
Inhibitory Effects Induced by Vicia faba, Uncaria rhyncophylla, and Glycyrrhiza glabra Water Extracts on Oxidative Stress Biomarkers and Dopamine Turnover in HypoE22 Cells and Isolated Rat Striatum Challenged with 6-Hydroxydopamine.Antioxidants (Basel). 2019 Nov 29;8(12):602. doi: 10.3390/antiox8120602. Antioxidants (Basel). 2019. PMID: 31795449 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical